MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue119.75149.687-194.494
Cost of Revenue6,787.4749,010.4993,947.6445,292.193
Gross Profit-6,667.724-8,860.812-3,947.644-5,097.699
Operating Expenses
Research Development----
Selling General and Administrative7,978.8217,641.5924,309.4894,813.8
Non Recurring----
Others----
Total Operating Expenses14,766.29516,652.0918,257.13310,105.993
Operating Income or Loss-14,646.545-16,502.404-8,257.133-9,911.499
Income from Continuing Operations
Total Other Income/Expenses Net56.552658.959658.396776.099
Earnings Before Interest and Taxes-14,646.545-16,502.404-8,257.133-9,911.499
Interest Expense-13-6-6-6
Income Before Tax-14,589.993-15,843.445-7,598.737-9,135.4
Income Tax Expense-506.92-356.956--
Minority Interest----
Net Income From Continuing Ops-14,083.073-15,486.489-7,598.737-9,135.4
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-14,083.073-15,486.489-7,598.737-9,135.4
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-14,988.116-32,836.188-11,992.546-9,135.4